Home » Stocks » ORMP

Oramed Pharmaceuticals Inc. (ORMP)

Stock Price: $10.94 USD 0.32 (3.01%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 330.70M
Revenue (ttm) 2.70M
Net Income (ttm) -15.46M
Shares Out 27.00M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $10.94
Previous Close $10.62
Change ($) 0.32
Change (%) 3.01%
Day's Open 10.86
Day's Range 10.64 - 11.20
Day's Volume 341,459
52-Week Range 2.40 - 12.73

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, April 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

2 weeks ago - PRNewsWire

NEW YORK, March 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

1 month ago - PRNewsWire

GURUGRAM, India--(BUSINESS WIRE)-- #Antibodies--Premas Biotech and Oramed announce Oral COVID-19 vaccine candidate that produces Antibodies after a single dose.

1 month ago - Business Wire

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) has entered into definitive agreements to form a joint venture focused on developing oral COVID-19 vaccines. The new company, Oravax Medical Inc, will use Orame...

1 month ago - Benzinga

NEW YORK, March 19, 2021 /PRNewswire/ -- Good candidate for protection against COVID variants due to triple antigen targeting  Implications for potential ease of widescale distribution and administratio...

1 month ago - PRNewsWire

NEW YORK, March 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery system...

1 month ago - PRNewsWire

NEW YORK, March 4, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

2 months ago - PRNewsWire

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

3 months ago - PRNewsWire

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

4 months ago - PRNewsWire

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

4 months ago - PRNewsWire

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

5 months ago - PRNewsWire

NEW YORK, Nov, 24, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems...

5 months ago - PRNewsWire

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems...

5 months ago - PRNewsWire

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

6 months ago - PRNewsWire

NEW YORK, Oct. 16, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

6 months ago - PRNewsWire

NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

7 months ago - PRNewsWire

NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc.

7 months ago - PRNewsWire

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc.

8 months ago - PRNewsWire

Pharmaceutical companies have poured millions—maybe billions—of dollars into research aimed at finding a way to deliver insulin to patients by mouth.

10 months ago - GuruFocus

NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

10 months ago - PRNewsWire

About ORMP

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a w... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
Nadav Kidron
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
ORMP
Full Company Profile

Financial Performance

In 2020, ORMP's revenue was $2.71 million, an increase of 0.26% compared to the previous year's $2.70 million. Losses were -$11.51 million, -19.81% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ORMP stock is "Strong Buy." The 12-month stock price forecast is 21.17, which is an increase of 93.51% from the latest price.

Price Target
$21.17
(93.51% upside)
Analyst Consensus: Strong Buy